Augmentation of radiation response with the vascular targeting agent ZD6126

Conclusions: These preclinical studies suggest that ZD6126 can augment the radiation response of proliferating endothelial H&N and lung cancer cells. These results complement recent reports suggesting the potential value of combining radiation with vascular targeting/antiangiogenic agents.